By: Richard Mark Kirkner From: medscape.com The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for disease progression or death by more than the current standard-of-care treatment. Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, presented this finding and other …
-
-
What Motivates You to Action After a Breast Cancer Diagnosis?
-
The 4th of July – Independence Day for This Breast Cancer Survivor
-
What Is Needed After Breast Cancer Surgery?
-
The Sadness Experienced by Some Breast Cancer Survivors
-
The Importance of Hope for Breast Cancer Survivors
